US/UK/Canada

Share

About Us

Gyros miniaturizes and integrates laboratory processes into application-specific Gyrolab? microlaboratories that process hundreds of samples in parallel at nanoliter scale. Scientists generate more information from less sample, improve lab performance and increase productivity.

Pick a time period -
Tags ( Active)

Gyros introduces new product for high concentration protein quantification

Uppsala, Sweden, 13 February, 2007. Gyros announced today that it has extended its product range with a new compact disc (CD) microlaboratory – Gyrolab Bioaffy® 20 HC – for dilution-free protein quantification in the grams per liter range.When quantifying proteins in high concentrations, current technologies, such as ELISA, require extensive dilution of samples in order to bring them into the technology’s measurable range. This is cumbersome and time consuming for scientists and increases the risk of quantification errors. By using very small sample volumes and a high-capacity capture

Gyros completes five new sales of its Gyrolab® protein quantification platform

Uppsala, Sweden, 13 February, 2007. Gyros announced today that it has completed the separate sales of five Gyrolab® microfluidic system platforms to Merck, Biogen-Idec and a third, unnamed company, all in the USA, and to NovImmune and Serono in Europe.Gyros microfluidic platform consists of Gyrolab Bioaffy® compact disk (CD) microlaboratories (facilitating miniaturized and integrated protein quantification applications) and Gyrolab Workstation (a fully automated system for running Gyrolab Bioaffy CDs). Together they provide a simple to use, precisely controlled solution for processing

Gyros platform for protein quantification purchased by AstraZeneca and Cambridge Antibody Technology

Uppsala, Sweden, 8 August, 2006. Gyros announced today that it has completed the separate sales of two microfluidic system platforms to AstraZeneca and Cambridge Antibody Technology (CAT).The system sales, which took place in April 2006 prior to the acquisition of CAT by AstraZeneca, signify the growing interest from major pharmaceutical and biopharmaceutical companies in the benefits offered by Gyros AB’s microfluidic technology. Gyros microfluidic platform consists of Gyrolab Bioaffy® compact disk (CD) microlaboratories (facilitating miniaturized and integrated protein quantification

Gyros awarded Frost & Sullivan Technology of the Year Award

Gyros announced today that it has been awarded Frost & Sullivan’s 2005 Excellence in Technology of the Year Award in the field of laboratory automation for Gyrolab™ automated system (Gyrolab Workstation).Frost & Sullivan’s Excellence in Technology Award is given to the company that has pioneered the development and introduction of an innovative technology into the market; a technology that has either impacted or has the potential to impact several market sectors. The award recognizes the company’s successful technology development that is expected to bring significant contributions to the

Gyros AB announces license and development agreement with Fujirebio Inc, Japan

Uppsala, Sweden, November 25, 2004 Gyros AB announced today that it has signed a non-exclusive license and development agreement with Fujirebio Inc. for diagnostic applications using Gyros’ proprietary Compact Disc technology.Under the terms of the agreement, Fujirebio will investigate combining Gyros’ Compact Disc technology with its own chemiluminescence immunoassay platform, in order to develop a new system for diagnostic applications. Jan Würtz, CEO & President of Gyros AB said; “Gyros has now reached an important milestone in its effort of commercialize its unique microfluidics

New appointment to boost Gyros sales worldwide

New appointment to boost Gyros sales worldwide Press Release, 04 October 2004 Uppsala, Sweden Gyros announced today that Mats Bergström joined the company on 01 October 2004 as Vice President, Marketing and Sales. Mr. Bergström brings with him a wealth of sales and marketing experience gained from over 20 years in the Life Science industry. Mr. Bergstöm joins Gyros from Pyrosequencing (part of Biotage AB), where he was Vice President, responsible for European sales and support as well as distributor organizations in Europe and Asia. Previous to this, Mr. Bergström spent eight years at

Gyros appoints Jan Würtz as Chief Executive Officer

Gyros appoints Jan Würtz as Chief Executive Officer Press Release, 02 July 2004 Uppsala, Sweden Gyros AB announced today the appointment of Mr. Jan Würtz as President and Chief Executive Officer within the company. Mr. Würtz has extensive executive experience gained within the Life Science industry and the diagnostics sector in particular. Mr. Würtz has over 20 years experience in the Life Science industry, beginning at Gambro Engström AB, where he was appointed Vice President, Marketing and Sales. Since then, Mr. Würtz has held several senior management positions within Pharmacia

Gyros and George Washington University step up collaboration

Gyros and George Washington University step up collaboration Gyros AB revealed today that its collaboration with George Washington University to evaluate and develop the recently launched Gyrolab Bioaffy(TM) is being stepped up, after a successful feasibility phase. Gyrolab Bioaffy is a solution for protein quantification, based on Gyros technology platform, in which single or multiplex immunoassays are performed at nanoliter scale in CD microlaboratories. Dr. Benjamin Dickens, Associate Research Professor, George Washington University has been evaluating the performance of Gyrolab Bioaffy

Gyros closes third funding round

Gyros closes third funding round The Swedish biotech company, Gyros AB, announced today the success of their third round funding. At a total of 145 million sek (~20 MUSD) this represents the largest private venture capital biotech investment in Scandinavia this year. The international consortium of investors led by Scandinavian Life Science Venture (SLSV) included Investor Growth Capital, Schroder Ventures Life Sciences, 3i, Ettena Förvaltnings AB (formerly SIF), Swedish Industrial Development Fund, InnovationsKapital, Health & Brand Capital and Life Equity Sweden. Jan Sundqvist, managing

Gyros appoints Chief Financial Officer

Gyros appoints Chief Financial Officer Gyros AB announced today the appointment of Björn Bontin as Chief Financial Officer and Investor Relations Manager within the company. Mr. Bontin comes from the business systems company IBS AB where he held the position of CFO and Investor Relations Manager. "Mr. Bontin has long experience of working in publicly listed companies and brings with him a strong network within the financial and analytical world." explained Dr. Maris Hartmanis, CEO at Gyros AB. "In addition, his experience of working in growing companies within an international environment

Gyros introduces new CD microlaboratory for Gyrolab MALDI users

Gyros introduces new CD microlaboratory for Gyrolab MALDI users Gyros AB announced today the introduction of a new CD microlaboratory, Gyrolab(TM) MALDI IMAC. Maris Hartmanis, President and CEO of Gyros AB explained, "Successful identification of proteins, especially those in low abundance, is crucial in proteomics and detection and identification of phosphorylated proteins is often a particular challenge. Gyrolab MALDI IMAC will offer users a unique solution for detection of phosphorylated peptides by MALDI mass spectrometry." This new method offers a smoother, more reliable solution as

Gyros previews next generation of Gyrolab Workstation for protein quantification at nanoliter scale

Gyros previews next generation of Gyrolab Workstation for protein quantification at nanoliter scale Gyros has decided to preview Gyrolab Workstation, with its new laser- induced fluorescence detector for protein quantification, at the American Society of Mass Spectrometry meeting in Montreal, Canada, June 8-12. Those who attend will have a possibility to obtain more information. The concept was presented at a recent meeting of the American Association of Immunologists. "Scientists can now run established sandwich-based immunoassays at nanoliter scale in a CD microlaboratory." explained Per

Gyros AB licenses patented technology to Cellectricon AB.

Gyros AB licenses patented technology to Cellectricon AB. Gyros AB today announced finalization of a licensing agreement with Cellectricon AB relating to a patent held by Gyros and applied in major biotech markets worldwide. Maris Hartmanis, President and CEO at Gyros AB explained "This is the second in a number of licensing agreements that we are pursuing. The patent held by Gyros is very wide ranging and covers the manufacture and use of elastomeric microfluidic devices." Jakob Lindberg CEO at Cellectricon added, "Processes covered by the Gyros patent are used within the development of

Gyros AB adds new functionality to Gyrolab MALDI SP1 and extends compatibility with MALDI instrumentation

Gyros AB adds new functionality to Gyrolab MALDI SP1 and extends compatibility with MALDI instrumentation Gyros AB announced today that users of Gyrolab MALDI can now employ the latest chemically assisted fragmentation when preparing protein digests for peptide sequencing by MALDI mass spectrometry (MALDI MS). MALDI MS is a key technique used for protein identification in proteomics. Gyrolab MALDI offers a unique, miniaturized and integrated process for sample preparation prior to MALDI MS that increases the success rate of protein identification, particularly when working with low

Gyros AB licenses patented technology to Fluidigm Corporation.

Gyros AB licenses patented technology to Fluidigm Corporation. Gyros AB and Fluidigm Corporation today announced finalization of a licensing agreement of a patent family held by Gyros which covers certain microfluidic devices based on elastomeric layers. The Gyros patent applies in the US (US Patent 5,376,252) and in additional major biotech markets worldwide. Maris Hartmanis, President and CEO at Gyros AB explained, "We are very pleased that Fluidigm has agreed to become the initial licensee of one of Gyros' early patent filings. We expect that additional companies will also sign up for

Gyros AB and Kratos Analytical collaboration is a success

Gyros AB and Kratos Analytical collaboration is a success Gyros AB today announced the success of their collaboration with Kratos Analytical, begun in May 2002. Users of the Axima-QITTM and Axima-CFRTM plus line of mass spectrometry workstations will soon be able to benefit from using GyrolabTM MALDI for sample preparation prior to analysis. Gyros offers a miniaturized and fully integrated process for sample preparation prior to MALDI mass spectrometry, using a microlaboratory in the form of a compact disk (CD), Gyrolab MALDI SP1, that can be run under automated conditions. Protein digests

Gyros AB continues expansion, opens German sales office.

Gyros AB continues expansion, opens German sales office. Gyros AB today announced the appointment of Dr. Winfried Girg as Sales Manager for the Company's new Munich-based subsidiary. This local sales organization will support clients based in Germany and Austria and is the next step in the Company's expansion throughout Europe. Dr. Girg comes from a highly successfully career in sales and marketing within Biacore AB, a leading supplier to medical and life science laboratories. "The German-speaking region represents one of the largest life science markets in Europe." explained Per Sjoberg,

Gyros AB expands European operations.

Gyros AB expands European operations. Gyros AB today announced the finalization of agreements with distributors B & L Systems in BeNeLux and Bucher Biotec in Switzerland to market and sell products based on the company's proprietary technology platform. "The market response to our recent product launch, Gyrolab MALDI, has encouraged us to continue our expansion into other European regions that have a high level of pharmaceutical and biotech activity." explained Per Sjoberg, Executive Vice President Commercial Operations at Gyros AB, "Local presence in key markets is a high priority at this

Former AstraZeneca R&D Head appointed New Chairman of Gyros AB

Former AstraZeneca R&D Head Appointed New Chairman of Gyros AB Gyros AB announced today the appointment of Dr. Claes Wilhelmsson as chairman of the board. Dr Wilhelmsson is the former Executive Director and Head of Research and Development at AstraZeneca and currently Senior Adviser to Investor Growth Capital, a wholly owned subsidiary of Investor AB. The appointment is effective immediately. "With our first commercial products already in the marketplace and more in the pipeline, it is invaluable for us to have the experience of such a renowned leader on our board," commented Maris

Gyros AB and Kratos Analytical begin development collaboration.

Gyros AB and Kratos Analytical begin development collaboration. Gyros AB today announced a collaboration agreement with Kratos Analytical to develop a microlaboratory for sample preparation prior to analysis by mass spectrometry to be based on the Gyros microfluidic technology platform. The microlaboratory will be compatible with the Axima-QIT(TM) and Axima-CFR(TM) line of mass spectrometry workstations from Kratos. Gyros have developed a miniaturized and fully integrated process for sample preparation prior to MALDI mass spectrometry, using a microlaboratory, Gyrolab MALDI SP1, in the form

Gyros AB increases successful second round funding.

Gyros AB increases successful second round funding. The Swedish biotech company, Gyros AB, today announced that Schroder Ventures Life Sciences had joined other key investors and added 6 MUSD to the company's successful second round funding. This brings the total raised in this round to approximately 36 MUSD. "We achieved one of the largest biotech venture fund raisings in Europe during 2001." explained Maris Hartmanis, President and CEO at Gyros, "But the door was left open for Schroder Ventures Life Sciences to join at a later date. We are delighted that they are demonstrating such

Gyros AB announces first commercial application: Gyrolab (TM) MALDI

Gyros AB announces first commercial application: Gyrolabtm MALDI. Gyros AB today announced the introduction of Gyrolabtm MALDI SP1 and Gyrolab Workstation, the company's first products based on its proprietary Gyrostm microfluidic technology platform. Gyrolab MALDI offers a unique, fully integrated process for sample preparation prior to MALDI mass spectrometry, an essential technique frequently used for protein identification in proteomics. This new approach to sample preparation gives those working in drug discovery a significant opportunity to increase the success rate of protein

There are no items matching the current filter
There are no more items matching the current filter
Back to top